Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.32 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.32 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 2/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.31 |
| ▸ | PLK4 | O00444 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | CHUK | O15111 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.31 |
| ▸ | INSR | P06213 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26096218 | 0.82 | MAP2K1 (0.36) | MAP2K1ERBB2LRRK2NTRK1AURKA | |
| SCHEMBL19104234 | 0.82 | ERBB2 (0.34) | MAP2K1ERBB2LRRK2MAPK1MAP2K4 | |
| SCHEMBL19115902 | 0.82 | ERBB2 (0.35) | MAP2K1ERBB2MAPK1GRM5 | |
| SCHEMBL3673625 | 0.80 | MAPK1 (0.47) | MAP2K1ERBB2LRRK2NTRK1MAPK1 | |
| SCHEMBL30201734 | 0.80 | MAPK1 (0.47) | MAP2K1ERBB2LRRK2NTRK1MAPK1 | |
| SCHEMBL18408664 | 0.76 | CYP1A2 (0.37) | MAPK1MAP2K4MAPKAPK2MAPK6CHEK1 | |
| SCHEMBL26577963 | 0.75 | — | — | |
| SCHEMBL23206119 | 0.73 | GAA (0.35) | MAPK1MAP2K4MAPKAPK2MAPK6CHEK1 | |
| SCHEMBL25667774 | 0.73 | MAPK1 (0.33) | MAPK1MAP2K4MAPKAPK2MAPK6AURKA | |
| SCHEMBL25667658 | 0.73 | MAPK1 (0.40) | MAPK1MAP2K4MAPKAPK2MAPK6CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203018-A1 | COVALENT INHIBITORS OF KRAS | ARAXES PHARMA LLC (US) | 2023-06-29 | — | — | US | disclosed |
| WO-2018140514-A1 | 1-(6-(3-HYDROXYNAPHTHALEN-1-YL)QUINAZOLIN-2-YL)AZETIDIN-1-YL)PROP-2-EN-1-ONE DERIVATIVES AND SIMILAR COMPOUNDS AS KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018140599-A1 | BENZOTHIOPHENE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018140512-A1 | FUSED BICYCLIC BENZOHETEROAROMATIC COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018140598-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018140600-A1 | FUSED HETERO-HETERO BICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018068017-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF RAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2018-04-12 | — | — | WO | disclosed |
| US-20170197945-A1 | 2-SUBSTITUTED QUINAZOLINE COMPOUNDS COMPRISING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203018-A1 | COVALENT INHIBITORS OF KRAS | KRAS, NRAS, HRAS | MAP2K1 250/4885ERBB2 218/4885LRRK2 79/4885 |
| US-20170197945-A1 | 2-SUBSTITUTED QUINAZOLINE COMPOUNDS COMPRISING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | MAP2K1 237/4885ERBB2 183/4885LRRK2 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.